Recently, the Hong Kong stock market's innovative drug sector has shown significant volatility. In just a few days, it first rose by 4.7%, then fell by 4.0%, and today it opened lower again. Nevertheless, the Hong Kong innovative drug ETF still maintains a premium status, reflecting investors' continued enthusiasm for this field.

In the past three days, the net inflow of funds in this sector exceeded 1.5 billion, with the share increasing by over 1 billion, indicating that many investors are taking advantage of the dip to increase their positions. This phenomenon has sparked discussions in the market about whether to continue adding investments and when to take profits.

From a positive perspective, China's research and development and production costs for innovative drugs have significant advantages globally. Even considering tariff factors, since innovative drugs usually adopt a licensing model where overseas pharmaceutical giants are responsible for production and sales, Chinese companies mainly receive licensing fees, thus the actual impact is limited.

In addition, the trend of population aging in China is becoming increasingly obvious, and the economic capacity of contemporary elderly people has significantly improved compared to previous generations. This means that the future pharmaceutical consumption market will continue to expand, whether relying on medical insurance or out-of-pocket expenses, bringing great opportunities to the innovative drug industry.

However, investors also need to be aware of the risks brought by market fluctuations. Although the innovative drug industry has a broad outlook, it also faces many uncertainties such as research and development failures and policy changes. Therefore, when making investment decisions, it is important to comprehensively consider various factors such as personal risk tolerance, market trends, and the long-term development trends of the industry.

For existing investors, it is advisable to set reasonable take-profit points and to realize profits moderately when expected returns are reached. At the same time, strategies such as building positions in batches or investing regularly with fixed amounts can be adopted to reduce the risks brought by market volatility.

Overall, the Hong Kong stock market's innovative pharmaceutical sector still contains enormous development potential. However, investors need to remain rational, closely monitor market trends and policy changes, and find a balance between opportunities and risks.